Rankings
▼
Calendar
PCVX
Vaxcyte, Inc.
$9B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$114M
Net Income
-$95M
EPS (Diluted)
$-0.85
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$159M
Free Cash Flow
-$171M
Stock-Based Comp.
$18M
Balance Sheet
Total Assets
$2.1B
Total Liabilities
$107M
Stockholders' Equity
$2.0B
Cash & Equivalents
$612M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$114M
-$71M
-60.8%
Net Income
-$95M
-$60M
-57.2%
← FY 2024
All Quarters
Q2 2024 →
PCVX Q1 2024 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena